Document is current

Any future updates will be listed below

Dordaviprone-the first and only approved treatment option for recurrent H3 K27M-mutant diffuse midline glioma – Letter to the editor

Crossref DOI link: https://doi.org/10.1007/s11845-025-04161-6

Published Online: 2025-11-10

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark